IMO 3100

Drug Profile

IMO 3100

Alternative Names: IMO-3100

Latest Information Update: 12 Feb 2016

Price : $50

At a glance

  • Originator Idera Pharmaceuticals
  • Class Anti-inflammatories; Oligonucleotides
  • Mechanism of Action Immunomodulators; Toll-like receptor 7 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hyperlipidaemia; Inflammatory bowel diseases; Multiple sclerosis; Plaque psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 11 Feb 2016 No development reported - Phase-II for Plaque psoriasis (Monotherapy) in USA (SC)
  • 15 May 2013 No development reported - Preclinical for Hyperlipidaemia in USA (unspecified route)
  • 15 May 2013 No development reported - Preclinical for Inflammatory bowel disease in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top